The first major national science and technology infrastructure for translational medicine was completed

Medicine Network December 22 - December 19, translational medicine's first major national science and technology infrastructure in Shanghai Jiao Jiao university medical school affiliated Ruijin Hospital was officially completed.
Three is the third state-level facility located in Shanghai after Shanghai Light Source Facility and Shanghai Protein Center, and the first state-level facility in the field of biomedicine in China, which will directly launch a scientific impact on key health issues.
years, the transformation of medical innovation has attracted much attention, and the state has set up transformational medical research facilities in Shanghai, Chengdu, Beijing and Xi'an to form a support network for translational medicine research covering the main regions of the country.
as one of the 16 major scientific and technological infrastructures prioritized during china's 12th Five-Year Plan period, this launch ceremony marks the official step of transforming medical facilities from the stage of comprehensive construction to the stage of leading the medical industry and developing at full speed.
Chinese Academy of Engineering, Ruijin Hospital President Ning Guang introduced, the facility is the first clinical medicine and basic research in one of the major scientific facilities, will be for China's major disease diagnosis and treatment of major key technologies, focusing on cancer, metabolic diseases and cardiovascular diseases and other fields, research related pathogenesis and laws, to solve the occurrence, development and transfer of major scientific problems.
through the construction of systematic, large-scale, integrated scientific facilities, from clinical practice to basic research, pharmaceutical products and technology development, and then back to clinical practice of translational medicine research.
the launch ceremony, experts jointly unveiled the European Society for Blood and Bone Marrow Transplantation China Clinical Innovation Cooperation Center, and held the "Translational Medicine Award" and "Chen Jialun Xuman Yin Education Fund" award ceremony.
Ruijin Hospital and Shanghai Pharmaceutical Group, Fosun Group, Xinda and other seven pharmaceutical industry leaders to complete the signing of cooperation, will be transformed medical technology research and development as the core sector, focusing on efforts to further enhance the two sides in the medical industry leading edge.
also held a forum on translational medicine, led by Chen Sai-yin, a member of the Chinese Academy of Engineering and director of the National Major Science and Technology Infrastructure of Translational Medicine (Shanghai), and a number of experts and scholars conducted in-depth discussions on major disease translational medicine research and cancer innovative treatment and drug research and development, and contributed to the inheritance and development of China's medical and health services, especially translational medicine.
。